



Docket No.: PF-0185-2 CON

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 7, 2003.

By: [Signature]

Printed: Lisa McDill

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: **Bandman et al.**

Title: **NOVEL ENDOTHELIAL GROWTH FACTOR**

Serial No.: **10/044,622**

Filing Date: **January 9, 2002**

Examiner: **Saoud, C.**

Group Art Unit: **1647**

---

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.


It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION



Date: November 7, 2003

Richard C. Ekstrom

Reg. No. 37,027

Direct Dial Telephone: (650) 843-7352


**Customer No.: 27904**

3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555

Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office		Atty Docket No.	Serial No.
		PF-0185 2 CON	10/044,622
 LIST OF REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)		Applicant(s)	
		Bandman et al.	
		Filing Date	Group
		January 9, 2002	1647

U.S. Patent Documents								
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	1**	5,194,596	1993-03-16	Tischer et al.				
Foreign Patent Documents								
							Translation	
		Document	Date	Country	Class	Subclass	Yes	No
	2**	WO9712972	1997-04-10	PCT				
	3**	WO9802543	1998-01-22	PCT				
	4**	WO9807832	1998-02-26	PCT				
	5**	WO9824811	1998-06-11	PCT				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	6	Carmeliet, P. et al., "Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele", <u>Nature</u> , 380:435-439 (1996)						
	7	Ferrara, N. et al., "Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene", <u>Nature</u> , 380:439-442 (1996)						
	8	Lee, J. et al., "Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4", <u>Proc. Natl. Acad. Sci. USA</u> , 93:1988-1992 (1996)						
	9	Aiello, L. et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and other Retinal Disorders", <u>The New England Journal of Medicine</u> , 331(22):1480-1487 (1994)						
	10	Aiello, L. et al., "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins", <u>Proc. Natl. Acad. Sci. USA</u> , 92:10457-10461 (1995)						
	11	Matzuk, M.M., "Functional Analysis of Mammalian Members of the Transforming Growth Factor-B Superfamily", <u>TEM</u> , Vol. 6, No. 4, 120-127 (1995)						
	12	Orlandini, M. et al., "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family," <u>PNAS</u> , 93:11675-11680 (1996)						

\*\*Submitted on CD-R: US5194596.pdf; WO9712972(A2,A3).pdf; WO9802543(A1).pdf; WO9807832(A1).pdf; WO9824811(A2,A3).pdf 14.0MB

Examiner	Date Considered
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.	